Table 1.
Patient and treatment characteristics
| Patient characteristics | N = 10 |
| n (%) | |
| Median age (range) years | 66 (55–77) |
| Female gender | 5 (50%) |
| ECOG performance status ≥ 2 | 2 (20%) |
| Ethnicity | |
| Hispanics | 4 (40%) |
| White | 3 (30%) |
| African American | 2 (20%) |
| Asian | 1 (10%) |
| Disease characteristics | n (%) |
| Non-GCB DLBCL | 4 (40%) |
| Transformed lymphoma | 3 (30%) |
| Double expressor lymphoma | 6 (60%) |
| Triple expressor lymphoma | 2 (20%) |
| Double hit lymphoma | 1 (10%) |
| Triple hit lymphoma | 1 (10%) |
| P53 deletion by FISH | 1 (10%) |
| Disease stage | |
| Stage I | 0 |
| Stage II | 1 (10%) |
| Stage III | 4 (40%) |
| Stage IV | 5 (50%) |
| Number of prior lines of therapy | |
| 1 | 0 |
| 2 | 2 (20%) |
| 3 | 3 (30%) |
| 4 | 5 (50%) |
| CNS involvement | 2 (20%) |
| Prior AHCT | 7 (70%) |
| Response to treatment | n (%) |
| CR at 3 months | 8 (80%) |
| POD | 1 (10%) |
| Adverse events | |
| CRS | 6 (60%) |
| CRS grade ≥ 2 | 2 (20%) |
| ICANS | 5 (50%) |
| ICANS grade ≥ 2 | 3 (30%) |
| Tocilizumab | 3 (30%) |
| Glucocorticoids | 1 (10%) |
| Neutropenia (< 500 c/μl) | 10 (100%) |
| Neutropenic fever | 8 (80%) |
| Thrombocytopenia (< 50,000 c/μl) | 7 (70%) |
| Documented infection | 5 (50%) |